Feature | Stents Bioresorbable | September 08, 2017| Dave Fornell

Abbott Will End Sales of Absorb Bioresorbable Stent

Low sales cited as reason for discontinuing commercial sales of the Absorb

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.

September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular scaffold as of Sept. 14, 2017. The company said low sales of the bioabsorbable stent led to the decision to stop offering the product.  

Sales of Absorb will end in all countries, according to Abbott. The company plans to continue the ongoing Absorb clinical trials to assess long-term outcomes after the scaffold has dissolved. Abbott said trial centers can continue to use their existing Absorb inventory, but as of Sept. 14, Abbott will not continue to supply the product. The trials will continue to follow already enrolled patients, but there will not be any new patients enrolled.  

“Due to low commercial sales, Abbott will stop selling the first-generation bioresorbable Absorb coronary stent,” Abbott stated on its website product section for the Absorb. “We pioneered bioresorbable technology because we believe it offers patients the possibility of life without permanent metallic implants, and we will continue work on a next generation bioresorbable device."

"First-generation products often go through iterations as experience is gained using them," said Abbott spokesman Jonathon Hamilton. "Absorb is a highly innovative ground-breaking device, and we're incorporating learnings into a second-generation product." 

The company said its metallic Xience drug-eluting stent (DES) will continue to be the cornerstone of Abbott’s vascular stent portfolio. The vendor also stated it will focus efforts on a next generation metallic DES, the Xience Sierra, which is supposed to offer improved deliverability and expanded sizes. 

The Absorb stent was originally hailed as a major advance forward in coronary stent technology when it received regulatory approval for commercial sales in Europe in 2011 and the United States in July 2016. However, as use of the stent expanded and new trial data revealed, it was found the scaffold has several limitations compared to metallic stents. These include delivery issues due to the thicker struts, stent recoil, the limited ability to over-expand without breaking struts, the need for very precise sizing, and poor outcomes if the Absorb is used in coronary vessels 2.5 mm or smaller. Perhaps the biggest barrier to wider adoption was the much higher price tag for Absorb over traditional metallic DES. 

While the Absorb also has some advantages over metallic stents, these were not enough to persuade interventional cardiologists to increase their usage.

Read the full article “Questions Remain on Future of Bioresorbable Stents article.” 

Watch a VIDEO with Gregg Stone, M.D., "Poor Outcomes for Bioresorbable Stents in Small Coronary Arteries."

These issues were brought up in discussions at numerous sessions that involved bioresorbable stents at the 2017 American College of Cardiology (ACC) meeting in March. Experienced users of the Absorb in trials said the stent can be used effectively, but that the new technology has a learning curve and it is not simply a replacement for metallic stents interventionalists have been using for two decades. Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, was key in these discussions at ACC with his presentation of the late-breaking two year outcomes of the ABSORB III trial of Absorb vs. Xience. Watch a VIDEO interview with Ellis, "Bioresorbable Stent Comparable to Xience at Two Years, With Concerns," or read the article on the ABSORB III results.  

 

Related Content on the Absorb Bioresorbable Scaffold:

Tempering the Bioresorbable Stent Euphoria Following FDA Clearance of the Absorb

VIDEO: Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development — a discussion with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation.

Bioresorbable Stent Comparable to Xience at Two Year, But With Adverse Trends

FDA Approves First Totally Bioresorbable Stent

VIDEO: Key Bioresorbable Stent Technology Presented at TCT 2015 — an interview with Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for both the ABSORB and SYNERGY stent trials.

Bioresorbable Stents Are the Way of the Future

The Future of Stent Development Depends on Bigger Improvements in Outcomes

 

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init